Screener
R&D at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | $2,272 | $8,699 | $40,518 | $17,874 |
| Operating expenses: | ||||
| Research and development | 51,293 | 43,469 | 98,733 | 84,091 |
| General and administrative | 24,781 | 17,989 | 46,884 | 36,346 |
| Total operating expenses | 76,074 | 61,458 | 145,617 | 120,437 |
| Loss from operations | (73,802) | (52,759) | (105,099) | (102,563) |
| Other income, net: | ||||
| Interest income | 4,722 | 2,372 | 10,013 | 5,247 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's R&D?
- Wave Life Sciences (WVE) reported R&D of $51.29M in Q2 2026.
- How has Wave Life Sciences's R&D changed year-over-year?
- Wave Life Sciences's R&D increased by 18.0% year-over-year, from $43.47M to $51.29M.
- What is the long-term trend for Wave Life Sciences's R&D?
- Over 4 years (2021 to 2025), Wave Life Sciences's R&D has grown at a 10.7% compound annual growth rate (CAGR), from $121.88M to $182.78M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Wave Life Sciences's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude